Gene · 8405
SPOP: speckle type BTB/POZ protein
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SPOP: speckle type BTB/POZ protein. Genes, record 8405. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8405
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O43791 | Speckle-type POZ protein | 374 | 36 | Ensembl, GeneID, HGNC |
Source UniProt
Patents111
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2025244125 A | 2025-11-27 | 27 | O43791 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 1023 | O43791 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 710 | O43791 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 710 | O43791 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 1023 | O43791 | Espacenet |
| WO 2025101862 A1 | 2025-05-15 | 33 | O43791 | Espacenet |
| EP 4509607 A2 | 2025-02-19 | 109 | O43791 | Espacenet |
| JP 2024178154 A | 2024-12-24 | 109 | O43791 | Espacenet |
| US 11459613 B2 | 2022-10-04 | 46 | O43791 | Espacenet |
| KR 1020220127513 A | 2022-09-20 | 1 | O43791 | Espacenet |
1 to 10 of 111
See all 111 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,321
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SPOP papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 58 | 2025 |
| P50CA097186 | The Pacific Northwest Prostate Cancer SPORE | 40 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 23 | 2025 |
| P01CA163227 | Androgen Receptor Action in Castration Resistant Prostate Cancer | 22 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 21 | 2025 |
| P50CA186786 | Michigan Prostate SPORE 2025-2030 | 20 | 2025 |
| P50CA092629 | SPORE in Prostate Cancer | 18 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 15 | 2025 |
| R01CA193837 | Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence | 11 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 9 | 2025 |
1 to 10 of 1,321Source NIH's project files
See all 1,321 nih grantsPapers2,215
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Association of ATM Alterations with Outcomes After 177Lu-PSMA-617 Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer. | J Nucl Med | 2026 | 42785951 | PubTator, text mining | PubMed |
| SPOP-mediated ZMYND8 ubiquitination and phase separation exclusion drives mTOR inhibitor resistance in kidney cancer. | Nat Commun | 2026 | 42778578 | PubTator, text mining | PubMed |
| Genomic and transcriptomic correlates of deep prostate-specific antigen response in patients with metastatic androgen pathway modulation-sensitive prostate cancer. | Oncologist | 2026 | 42752828 | PubTator, text mining | PubMed |
| Intratumoral Human Papillomavirus in Advanced Prostate Cancer: Systematic Review, Meta-Analysis, and Real-World Evidence from the Largest Cohort to Date. | Int J Mol Sci | 2026 | 42737728 | PubTator, text mining | PubMed |
| Erratum: The RNA helicase DDX17 enhances androgen receptor stability by interacting with the E3 ubiquitin ligase SPOP in prostate cancer. | Transl Androl Urol | 2026 | 42729183 | PubTator, text mining | PubMed |
| IL-23 promotes PD-L1 expression and tumor immune evasion via METTL16 pathway. | Am J Cancer Res | 2026 | 42724552 | PubTator, text mining | PubMed |
| Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer. | Prostate Cancer Prostatic Dis | 2026 | 42697914 | PubTator, text mining | PubMed |
| Proteo-genomics-guided interpretation of somatic mutations in cancer genomes. | Cancer Cell | 2026 | 42628524 | PubTator, text mining | PubMed |
| Double donut versus filament: How structural shapes regulate SPOP activity and cancer pathogenesis. | Mol Cell | 2026 | 42561922 | PubTator, text mining | PubMed |
| Early-Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection. | MedComm (2020) | 2026 | 42488705 | PubTator, text mining | PubMed |
1 to 10 of 2,215
See all 2,215 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/8405
GET https://conductscience.org/api/genes/v1/8405/patents?page=2